Rubin R. Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?. JAMA. 2024 May 14;331 (18):1519-1521. PubMed.

Nov 25, 2015 · AD Target / Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within …

Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. Epub 2019 Apr 12 PubMed.

Lee TS, Park EJ, Choi M, Oh HS, An Y, Kim T, Kim TH, Shin BS, Shin S. Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain …

Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults.

Zhang L, Zhang L, Li L, Hölscher C. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease. J Parkinsons Dis. 2019;9 …

Zhang Y, Tang C, He Y, Zhang Y, Li Q, Zhang T, Zhao B, Tong A, Zhong Q, Zhong Z. Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and …

May 14, 2024 · Lixisenatide is one of four GLP-1 mimetics being tested for Alzheimer’s or Parkinson’s diseases. It is a 44-amino acid peptide closely related to exenatide (Leon et al., …

Empagliflozin belongs to the gliflozin class of glucose-lowering agents that includes dapagliflozin. These drugs inhibit the sodium-glucose cotransporter-2 (SGLT2), which is responsible for 90 …

Sep 23, 2024 · Background Liraglutide is an analog of glucagon-like peptide 1. GLP-1 is a hormone that is produced in the gut and activates receptors in the gut, liver, and pancreas to …